Lipocine (NASDAQ:LPCN) CEO Purchases $50,500.00 in Stock

Lipocine Inc. (NASDAQ:LPCN) CEO Mahesh Patel purchased 25,000 shares of the stock in a transaction on Thursday, April 2nd. The shares were bought at an average price of $2.02 per share, for a total transaction of $50,500.00. Following the acquisition, the chief executive officer owned 135,679 shares of the company’s stock, valued at approximately $274,071.58. The trade was a 22.59% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Lipocine Stock Down 77.8%

Shares of NASDAQ:LPCN traded down $7.20 during trading on Thursday, reaching $2.05. The stock had a trading volume of 7,262,443 shares, compared to its average volume of 242,945. The stock has a fifty day simple moving average of $8.62 and a two-hundred day simple moving average of $5.77. Lipocine Inc. has a 52 week low of $1.81 and a 52 week high of $12.37. The firm has a market capitalization of $14.97 million, a price-to-earnings ratio of -1.22 and a beta of 1.09.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.26. The business had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.12 million. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%.

Institutional Trading of Lipocine

Several hedge funds and other institutional investors have recently bought and sold shares of LPCN. Citadel Advisors LLC acquired a new position in shares of Lipocine during the third quarter valued at about $41,000. Squadron Capital Management LLC bought a new position in Lipocine during the fourth quarter valued at about $4,256,000. Diadema Partners LP acquired a new position in Lipocine in the 4th quarter valued at approximately $2,095,000. Ikarian Capital LLC acquired a new position in Lipocine in the 4th quarter valued at approximately $1,602,000. Finally, Geode Capital Management LLC lifted its position in shares of Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after acquiring an additional 1,374 shares during the period. 9.11% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LPCN has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective (up from $7.00) on shares of Lipocine in a research note on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. Finally, Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.